Genprex regains Nasdaq stockholders' equity compliance; bid price issue unresolved

Genprex, Inc.

Received Nasdaq confirmation on June 6, 2025 that it regained compliance with stockholders' equity requirement of $2.5M.
Previously reported non-compliance with minimum bid price of $1.00 per share; compliance period ends August 6, 2025.
Company may consider reverse stock split or other options to regain bid price compliance; delisting risk remains.

item 3.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.